Johan Vansteenkiste

发表

Comparison of integrates PET-CT and remediastinoscopy te restage IIIA-N2 NSCLC after induction chemotherapy

K Pat, Johan Vansteenkiste, 2007 .

IV iron improves efficacy of ESA therapy with Darbepoetin alfa for patients with chemotherapy-induced anaemia

K Pat, Johan Vansteenkiste, I Wauters, 2008 .

Invasive mediastinal staging of lung cancer: ACCP evidence-based clinical practice guidelines (2nd edition).

Michael Wallace, Johan Vansteenkiste, G. Silvestri, 2007, Chest.

Randomized phase II study of three doses of the integrin inhibitor cilengitide versus docetaxel as second-line treatment for patients with advanced non-small-cell lung cancer

Johan Vansteenkiste, J. von Pawel, J. Vansteenkiste, 2009, Investigational New Drugs.

Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer.

Johan Vansteenkiste, G. Scagliotti, Keunchil Park, 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Cisplatin-based adjuvant chemotherapy in patients with completely resected non-small-cell lung cancer.

Bengt Bergman, Rodrigo Arriagada, Johan Vansteenkiste, 2004, The New England journal of medicine.

Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma

Johan Vansteenkiste, Johan Vansteenkiste, Sofie Derijcke, 2009 .

The IASLC Lung Cancer Staging Project: Summary of Proposals for Revisions of the Classification of Lung Cancers with Multiple Pulmonary Sites of Involvement in the Forthcoming Eighth Edition of the TNM Classification

Fergus Gleeson, Heber MacMahon, Jin Mo Goo, 2016, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

The role of PET scan in diagnosis, staging, and management of non-small cell lung cancer.

Johan Vansteenkiste, Christophe Dooms, C. Dooms, 2004, The oncologist.

The maximum uptake of 18F-deoxyglucose on positron emission tomography scan correlates with survival, hypoxia inducible factor-1α and GLUT-1 in non-small cell lung cancer

Sigrid Stroobants, Philippe Lambin, Cary Dehing-Oberije, 2007 .

Intracranial and whole-body response of ceritinib in ALK inhibitor-naïve and previously ALK inhibitor-treated patients with ALK-rearranged non-small-cell lung cancer (NSCLC): updated results from the phase 1, multicentre, open-label ASCEND-1 trial

Michael Thomas, Armando Santoro, Martin Schuler, 2016, The Lancet. Oncology.

Predictive gene signature in MAGE-A3 antigen-specific cancer immunotherapy.

Bart Spiessens, Benjamin Dizier, Stefan Suciu, 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society International Multidisciplinary Classification of Lung Adenocarcinoma

Masahiro Tsuboi, Iver Petersen, Hisao Asamura, 2011, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

IASLC MULTIDISCIPLINARY RECOMMENDATIONS FOR PATHOLOGIC ASSESSMENT OF LUNG CANCER RESECTION SPECIMENS FOLLOWING NEOADJUVANT THERAPY.

Prasad Adusumilli, Young Tae Kim, Ugo Pastorino, 2020, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Methods to monitor response to chemotherapy in non-small cell lung cancer with 18F-FDG PET.

Johan Nuyts, Otto S Hoekstra, Adriaan A Lammertsma, 2002, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

Selumetinib plus docetaxel for KRAS-mutant advanced non-small-cell lung cancer: a randomised, multicentre, placebo-controlled, phase 2 study.

Lucio Crinò, Carlos Barrios, Johan Vansteenkiste, 2013, The Lancet. Oncology.

Prognostic relevance of response evaluation using [18F]-2-fluoro-2-deoxy-D-glucose positron emission tomography in patients with locally advanced non-small-cell lung cancer.

Otto S Hoekstra, Adriaan A Lammertsma, Johan Vansteenkiste, 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

The maximum uptake of (18)F-deoxyglucose on positron emission tomography scan correlates with survival, hypoxia inducible factor-1alpha and GLUT-1 in non-small cell lung cancer.

Philippe Lambin, Cary Dehing-Oberije, Dirk De Ruysscher, 2007, European journal of cancer.

Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (The IDEAL 1 Trial) [corrected].

Masahiro Fukuoka, Yutaka Nishiwaki, Danny Rischin, 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

The impact of 18F-fluoro-2-deoxy-d-glucose positron emission tomography (FDG-PET) lymph node staging on the radiation treatment volumes in patients with non-small cell lung cancer

Gerald J. Kutcher, Sigrid Stroobants, Dominique Huyskens, 2000 .

Association of gene expression signature and clinical efficacy of MAGE-A3 antigen-specific cancer immunotherapeutic (ASCI) as adjuvant therapy in resected stage IB/II non-small cell lung cancer (NSCLC)

Jamila Louahed, Marcin Zieliński, Vincent Brichard, 2008 .